Cancer Center Support Grant

总体：项目摘要 华盛顿大学和巴恩斯犹太医院的Alvin J. Siteman癌症中心（SCC）是一个NCI 指定的综合癌症中心，其使命是在社区预防癌症， 通过科学发现治疗癌症患者。SCC通过强大的研究来完成这一使命 方案、共享资源支持、教育和培训、试点资助方案和社区外展。 我们的七个多学科研究项目促进了转化研究和科学发现 和10个共享资源（本申请中要求的第11个）是由我们82个县的患者需求驱动的 整个密苏里州和伊利诺斯州南部的集水区。 本中心从来自四所学校和23个部门的230名成员中选拔优秀人才， 为了进一步了解癌症途径的机制，加速从实验室到床边的管道， 实施预防策略，影响癌症筛查，发病率和死亡率在我们的集水区。 SCC的乳腺癌研究、造血发育和造血功能、癌症机制 生物学、肿瘤成像、预防和控制、实体瘤治疗和肿瘤免疫学 研究计划促进新的，多学科的癌症研究，并鼓励内部，间，和交叉， 机构合作。SCC在项目期间的关键指标证明了成功;以下数据为最新数据 每一个都代表了该中心的历史最高水平： NCI资金-直接4100万美元，不包括CCSG美元 * 大额合作赠款的数量-72 ·干预性临床试验应计费用-2018年为5，071 以癌症为重点的出版物总数-2018年为1，148; 35%为项目内或项目间出版物 高影响力出版物-2018年201（> 10.0 IF） 在接下来的五年里，SCC将通过卓越的研究和临床护理来推进其使命， 特别强调四个首要的科学主题，以最佳地利用和放大中心的 对癌症的影响。这些科学支柱是：基因组学及其在 临床护理;成像技术的创新及其在癌症诊断和治疗中的应用;免疫学 使用独特的免疫疗法加强患者护理;预防，以减轻 我们所服务的患者群体中的疾病。这些核心优势与SCC当前的战略计划相一致， 告知研究计划的目的，目标和举措。

OVERALL: PROJECT SUMMARY The Alvin J. Siteman Cancer Center (SCC) at Washington University and Barnes-Jewish Hospital is a NCI designated Comprehensive Cancer Center whose mission is to prevent cancer in the community and transform cancer patient care through scientific discovery. SCC accomplishes this mission through strong research programs, shared resource support, education and training, pilot funding programs, and community outreach. The translational research and scientific discovery facilitated by our seven multidisciplinary research programs and 10 shared resources (11th requested in this application) is driven by the needs of patients in our 82-county catchment area throughout Missouri and southern Illinois. The center applies the exceptional talent among our 230 members, from four schools and 23 departments, to further understand the mechanisms of cancer pathways, speed the conduit from bench to bedside, and implement prevention strategies that impact cancer screening, incidence, and mortality in our catchment area. SCC’s Breast Cancer Research, Hematopoietic Development and Malignancy, Mechanisms of Cancer Biology, Oncologic Imaging, Prevention and Control, Solid Tumor Therapeutics, and Tumor Immunology Research Programs promote novel, multidisciplinary cancer research and encourage intra, inter, and cross- institution collaboration. Success is evidenced by SCC’s key metrics in the project period; data below are current as of this application and each represents an all-time high for the center:  NCI funding – $41.0M direct, excluding CCSG dollars  Number of large collaborative grants – 72  Interventional clinical trial accruals – 5,071 in 2018  Total cancer-focused publications – 1,148 in 2018; 35% intra- or inter-programmatic  High Impact Publications – 201 in 2018 (> 10.0 IF) In the next five years, SCC will advance its mission through exceptional research and clinical care, with special emphasis on four overarching scientific themes chosen to optimally harness and magnify the center’s impact on cancer in the field and in our catchment. These scientific pillars are: genomics and its application to clinical care; innovation in imaging technologies and their use in cancer diagnosis and treatment; immunology and the enhancement of patient care using unique immune therapies; and prevention, to reduce the burden of disease in the population of patients we serve. These core strengths align with SCC’s current strategic plan and inform research program aims, objectives, and initiatives.